Navigation Links
Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology

velo.com/">www.nuvelo.com or by phoning 650-517-8000.

Kirin Brewery's Pharmaceutical Division is committed to providing innovative pharmaceuticals to patients in the field of kidney diseases, cancer (including hematological disorders), immunological diseases, and infectious diseases by using its unique and strong biotechnology. Kirin Brewery's Pharmaceutical Division has established operations in Asian countries and will expand globally including North America and Europe as a specialty pharmaceutical company. For more information on Kirin Brewery's Pharmaceutical Division, please visit its website at http://www.kirin.co.jp/english/index.html.

This press release contains "forward-looking statements," which include statements regarding the potential uses of NU206 to treat various conditions, the timing and progress of Nuvelo's clinical stage and preclinical research programs, and the potential utility of other Nuvelo compounds to treat particular indications, which statements are hereby identified as "forward- looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; and dependence upon strategic partners for the performance of critical activities under collaborative agreements. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Annual Report on Form 10-K for the year ended December 31, 2006 and subsequent filings. We disclaim any intent o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/28/2014)... Kalifornien, 28. August 2014 ... Start der Patientenrekrutierung für eine IDE-Pivot-Studie ... zur Beurteilung der Sicherheit und Wirksamkeit ... Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, Dozent ... of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der ...
(Date:8/28/2014)... ALISO VIEJO, Calif. , Aug. 28, 2014 ... has initiated patient enrollment in an Investigational Device ... and effectiveness of the WEB™ Aneurysm Embolization System ... University of Tennessee Department of Neurosurgery/Semmes-Murphey Clinic and ... first four patients in the study, treating them with ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3
... GNVC ) announced that Adel A.F. Mahmoud, M.D., ... the Company,s Board of Directors at its annual meeting of ... "Drs. Mahmoud and Connor bring a wealth of experience, especially ... expand the breadth and scope of our vaccine programs there ...
... June 22, 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), ... that it will hold a conference call with the ... Eastern (9:00 a.m. Pacific).  The Company,s Chairman and Chief ... on the business, and discuss the clinical and commercial ...
Cached Medicine Technology:GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 2GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 3GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 4Genesis Biopharma to Hold Business Update Conference Call on June 29 2
(Date:8/28/2014)... TX (PRWEB) August 28, 2014 After ... Dr. Paul Vitenas is excited to announce the ... of its kind in any city, Mirror Mirror Beauty ... building. , Situated on the corner of Richmond and ... modern architecture, luxurious amenities, and cutting-edge technology in a ...
(Date:8/28/2014)... Having greater amounts of yellow pigment in your eyes ... hazy conditions, a new study reports. In a ... in order to test the distance vision of people ... pigment) in their eyes. The volunteers had widely ... the nutrients lutein and zeaxanthin, according to the researchers, ...
(Date:8/28/2014)... The Foundation for Women’s Cancer ... September by alerting women to the link between obesity ... symptoms of endometrial cancer. , Endometrial cancer is ... common cancer. More than 52,600 will learn of a ... women with weight management challenges to know the early ...
(Date:8/28/2014)... Diego, CA (PRWEB) August 28, 2014 Vitals, ... has named Dr. Sabrina Fabi of Cosmetic Laser Dermatology one ... allows hundreds of thousands of patients to share their doctor ... including bedside manner, face time, and follow-ups. The Vitals Top ... in California, Dr. Fabi was ranked one of the highest ...
(Date:8/28/2014)... 28, 2014 Dr. Bryan McIntosh of ... ebook guide to the tummy tuck cosmetic procedure, ... the procedure itself, and how to recover well afterwards. ... explanations. Dr. McIntosh also discusses how to have accurate ... that the procedure is as successful as possible. , ...
Breaking Medicine News(10 mins):Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Foundation for Women's Cancer Alerts Women to Link Between Obesity and Endometrial Cancer 2Health News:Dr. Sabrina Fabi of Cosmetic Laser Dermatology Recognized as Vitals Top 10 Doctor 2Health News:The Ultimate Guide to the Tummy Tuck Surgery eBook is Released by Dr. Bryan McIntosh 2
... networks begin with one altruistic living donor, study explains, ... one healthy young man stepped forward, willing to give ... years later, 10 people had received new kidneys from ... donation started the first nonsimultaneous, extended altruistic-donor (NEAD) chain. ...
... report finds , , WEDNESDAY, March 11 (HealthDay News) -- Thousands ... by atmospheric ozone, a new study finds. , The greatest ... such as Los Angeles, which has one of the highest ... 25 percent to 30 percent higher annual risk of dying ...
... The Coalition for Ethical Imaging (CEI), a grassroots ... in Texas, has announced its support for Senate Bill ... bill in the House, House Bill 2599 by Rep. ... patient care and safety in the state of Texas ...
... BALTIMORE, March 11 The Open Society Institute,s Closing ... exist for the new Director of the Office of ... the United States, approach to the problem of addiction. ... Gil Kerlikowske,s official nomination as the nation,s "drug czar," ...
... Kidney Month Briefing Reveals Majority of New Kidney Failure ... Disproportionate Rates -WASHINGTON, March 11 Kidney Care Partners ... dialysis professionals, care providers and manufacturers working together to ... disease and kidney failure -- in partnership with the ...
... The American Association of Oral and Maxillofacial Surgeons ... on her recent introduction of H.R. 1339, the ... , which would require insurance plans, including those which ... (ERISA) , that provide surgical benefits, to cover reconstructive ...
Cached Medicine News:Health News:Living Kidney Donation Chains May Help More Get Transplants 2Health News:Living Kidney Donation Chains May Help More Get Transplants 3Health News:Ozone Pollution Taking Toll on American Lives 2Health News:Ozone Pollution Taking Toll on American Lives 3Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 2Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 3Health News:Closing the Addiction Treatment Gap Initiative Highlights Opportunities for New 'Drug Czar' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 3Health News:Oral and Maxillofacial Surgeons Applaud Congresswoman McCarthy's Legislation to Require Insurance Coverage for Children With Congenital Deformities 2Health News:Oral and Maxillofacial Surgeons Applaud Congresswoman McCarthy's Legislation to Require Insurance Coverage for Children With Congenital Deformities 3
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
... 50 analyzer is an ... offices and smaller laboratories ... of state-of-the-art instrument-based testing ... efficient way to obtain ...
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: